ASCO 2019 | Neoadjuvant atezolizumab in NSCLC

David Kwiatkowski

David Kwiatkowski, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outline a study investigating the use of neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics